About Kedrion
Kedrion is a Healthcare company based in Barga (Italy) founded in 2001, and was acquired by Permira in January 2022. Plasma-derived therapies are developed for hemophilia and immune deficiencies. Kedrion has raised $188.56 million across 3 funding rounds from investors including Permira, CDP Equity and IMI Fondi Chiusi SGR. Its website kedrion.com draws about 41 thousand monthly visits. Its Indian entity Kedrion Biopharma India Private Limited reported revenue of ₹28.36 Cr. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting.
Company details
Founded in 2001 and headquartered in Barga, Italy, Kedrion operates in the biotechnology sector. Blood plasma is collected and fractionated to produce therapies addressing hemophilia, immune system deficiencies, and critical care needs, including Albumin and Anti-D Immunoglobulin (RhoGAM) for preventing hemolytic disease in newborns. Efforts are focused on expanding the pipeline in hematology, immunology, and critical care areas.
- Headquarters Barga, Italy
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website kedrion.com
- Social LinkedIn
- Acquired by Permira (Jan 2022)
- Legal Name Kedrion Biopharma India Private Limited
- Date of Incorporation 06 Dec, 2013
- Jurisdiction New Delhi, Delhi, India
Associated legal entities of Kedrion
Kedrion operates through Kedrion Biopharma India Private Limited (under liquidation). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2021) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Kedrion Biopharma India Private Limited CIN U52100DL2013FTC261763 | Under Liquidation | 06 Dec 2013 | New Delhi, Delhi | ₹28.4 Cr | 3 | View details |
Funding Insights of Kedrion
Kedrion has successfully raised a total of $188.56M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $188.56M
- Total Rounds 3
- Investors Count 2
All 3 funding rounds of Kedrion with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2019 | Private Equity Round | – | – | – | |
| Jul 2012 | $188.56M | Series E | – | CDP Equity | – |
| Jun 2003 | Seed | – | – |
4 investors in total: 4 institutional.
Investors in Kedrion
Kedrion has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Permira, CDP Equity and IMI Fondi Chiusi SGR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investment firm focused on buyouts | cdpequity.it | Milan, Italy | ||
| imifondichiusisgr.com | ||||
Investments are made in technology, consumer, healthcare, and service sectors. | 1985 | permira.com | London, United Kingdom | |
Investor details for Kedrion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Kedrion Biopharma India Private Limited (Kedrion)
Kedrion Biopharma India Private Limited is the primary company behind Kedrion. The board of Kedrion Biopharma India Private Limited currently have 3 directors; the longest-serving is Avninder Singh, appointed in 2013. 7 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Avninder Singh DIN 06699929 | Director | 06 Dec 2013 | 12 yrs 11 mo | Kedrion Biopharma India Private Limited |
| Ferdinando Borgese DIN 07813527 | Managing Director | 07 Jul 2017 | 9 yrs 4 mo | Kedrion Biopharma India Private Limited |
| Vijay Khurana DIN 00030532 | Director | 16 Oct 2020 | 6 yrs | Kedrion Biopharma India Private Limited |
People of Kedrion
206 people are tracked at Kedrion (63 in leadership, 143 in team).
| Name | Role | Group |
|---|---|---|
Heather Lally | Regional Sales Director | Leadership |
Federico Rolando | Commercial Director - Latam & Canada | Leadership |
Duccio Manetti | Group Chief Communications & Government Affairs Officer | Leadership |
Barbara Giulianetti | Quality Sr. Director | Leadership |
Paolo Morabito | Pharmacovigilance Safety Director & Deputy Eu/uk QPPV | Leadership |
Nicola Galtieri | Head Of Global Ethics & Compliance | Leadership |
Marco Tinacci | Vice President, Group Consolidation, Administration & Taxes And Subsidiary Oversight | Leadership |
Davide Caramagno | People & Organization Development Global Director | Leadership |
Erika Dobos | Supply Chain Director | Leadership |
Anna Sorelli | Regulatory Affairs Director - Lifecycle Management & Europe | Leadership |
Steve Higgins | Corporate Accounts Director | Leadership |
Sarah Kingsland | Head Of Bioanalytics, GMSD Elstree | Leadership |
Ahmad Harastani | Vice President Commercial Operations - Asia & Russia | Leadership |
Eric Wolkoff | Corporate Account Director | Leadership |
Alessandro Bizzarri | Global Pharmacovigilance Senior Director & EU QPPV | Leadership |
Michael Enticott | Sales & Marketing Director | Leadership |
Edit Albert | Head Of Gxp Compliance Group | Leadership |
Miranda Norton | Scientific Director | Leadership |
Jim Spagnola | Regional Sales Director | Leadership |
Elisa Moretti | Global Pathogen Safety Senior Director | Leadership |
186 more people are available in the full profile.
Complete people profiles for Kedrion
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Kedrion
Figures of Kedrion Biopharma India Private Limited, the primary company behind Kedrion, for FY 2021. Revenue was ₹28.36 Cr (-10% year on year). Net loss was -₹4.79 Cr (-17% margin). EBITDA was -₹4.70 Cr (-17% margin). Revenue has grown at a compounded annual rate of +25% over three years and +32% over five years.
- ₹28.36 CrRevenue · FY 2021 · -10% YoY
- -₹4.79 CrNet loss · -17% margin
- -₹4.70 CrEBITDA · -17% margin
- ₹1.29 CrPaid-up capital
- +25%Revenue CAGR, 3 years
- +32%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Kedrion Biopharma India Private Limited are on its company page.
Detailed financial statements for Kedrion
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Kedrion
4 dated milestones of Kedrion across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Kedrion is founded.
- Funding First funding round.
- Funding Latest funding round, Private Equity Round,.
- Exit Acquired by Permira.
Web traffic of Kedrion
The website of Kedrion (kedrion.com) receives about 41.4K visits a month and ranks #612,048 among all websites worldwide, #660 in Biotechnology and Pharmaceuticals.
- Monthly visits41.4K
▼ 3% vs previous month
- Unique visitors12.9K
per month
- Global rank#612,048
among all websites
- Category rank#660
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit4.3
- Average visit1 min 59 sec
- DevicesDesktop 30% · Mobile 70%
Websites whose visitors overlap most with Kedrion. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
cadigroup.it | cadigroup.it | 100% | #5,483,804 | – | |
sofarmamorra.it | sofarmamorra.it | 84% | #1,165,439 | – | |
pptaglobal.org | pptaglobal.org | 82% | #1,548,204 | – | |
sch-plough.com | sch-plough.com | 82% | – | ||
| pfizer.com | 82% | 1.9M | #24,984 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 24 similar websites and full traffic analytics for Kedrion
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kedrion
Complete news archive for Kedrion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kedrion
Kedrion was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Kedrion is headquartered in Barga, Italy. It is registered at Barga, Tuscany, Italy.
Kedrion is a funded company, having raised a total of $188.56M across 3 funding rounds to date.
The primary company behind Kedrion, Kedrion Biopharma India Private Limited, reported revenue of ₹28.36 Cr for FY 2021, down 10% year on year.
Founded in 2001 and headquartered in Barga, Italy, Kedrion operates in the biotechnology sector. Blood plasma is collected and fractionated to produce therapies addressing hemophilia, immune system deficiencies, and critical care needs, including Albumin and Anti-D Immunoglobulin (RhoGAM) for preventing hemolytic disease in newborns. Efforts are focused on expanding the pipeline in hematology, immunology, and critical care areas.
Kedrion has 4 investors. Key investors include Permira, CDP Equity, IMI Fondi Chiusi SGR, and Marcucci family.
Kedrion operates through Kedrion Biopharma India Private Limited.
Yes. Kedrion was acquired by Permira in January 2022.
The legal entities of Kedrion currently have 3 directors, including Ferdinando Borgese, Vijay Khurana, Avninder Singh.